Abstract: A composition comprising a pigment particle that is coated with a cationic material and isopropyl titanium tri-isostearate. The pigment particle can be included in a cleansing composition for deposition on a surface, such as skin.

Abstract: A polymeric composition includes poly(lactide-co-glycolide) (PLGA) microspheres; and at least one of a discrete RSNO adduct or a polymeric RSNO encapsulated within the microspheres, with the at least one of the discrete RSNO adduct or the polymeric RSNO adduct capable of releasing nitric oxide (NO). The polymeric composition exhibits stability under dry conditions at 37° C. and prolonged and controllable NO release rates, when exposed to light capable of photolyzing an RSNO bond, or when exposed to moisture, for a predetermined amount of time from the at least one of the discrete RSNO adduct or the polymeric RSNO adduct.

Abstract: Provided herein is a tablet comprising 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol or a pharmaceutically acceptable salt thereof.

Abstract: Provided herein are solid form water soluble curcuminoid compositions, including a curcuminoid; and a solubilization matrix, wherein the solubilization matrix is selected from one or more of the following: (i) chlorophyllin (CHL); (ii) green tea extract; (iii) epigallocatechin gallate (EGCG); (iv) Rutin; and (v) an aromatic amino acid. Alternatively, the solubilization matrix may include methylsulfonylmethane (MSM). Also provided herein are methods for producing curcuminoid compositions.

Abstract: A method and system to prevent sore throat infections in humans includes the administration of an active ingredient to a site on the mucus membranes of the throat of a human that inhibits adherence and promotes desorption of S. pyogenes to soft tissue surfaces, such as the pharyngeal and oral mucosa of a human. A mucoadhesive strip having a surface topography that resists bioadhesion of undesired bacteria that are typically present in a human's mouth is preferably employed and that has one or more encapsulated agents selected from the group consisting of an antibiotic; lactic acid bacteria; S. pyogenes modified by a CRISPR-Cas system to reduce one or more virulence factors; and a breath mint solution.

Abstract: The Dissolvable Solid Structure as described herein can be in the form of a fibrous structure comprising: (a) a polymeric structurant; (b) a high melting point fatty compound such as a fatty amphiphile, and (c) a cationic surfactant. The polymeric structurant has a weight average molecular weight of from about 10,000 to about 6,000,000 g/mol, and the components of the fibrous material form a homogenous material when molten. When water is added to the dissolvable solid structure at a ratio of about 5:1 a lamellar structure is formed.

Abstract: An object of the present invention is to provide a feces treatment agent for colostomy, which on the assumption that characteristics required as a lubricant are shown, can maintain or improve the feces discharge properties from a colostomy pouch, inhibit the development of feces odor, and improve operativity and portability. A feces treatment agent for colostomy, in which an agent A including (1) a granular water-soluble lubricant, (2) a granular water-absorbing gelling agent, (3) sodium bicarbonate, and (4) a component including at least one selected from the group consisting of zinc oxide, limonite and zinc sulfide is contained in a water-soluble base material.

Abstract: The invention relates to novel antimicrobial surfactants and their application in antimicrobial coating systems, in particular water borne coatings. Provided is a method for providing an antimicrobial surfactant, comprising the steps of: (a) providing a hyperbranched polyurea having blocked isocyanates at the end of the polymer branches by the polycondensation of AB2 monomers; (b) introducing tertiary amine groups by reacting said blocked isocyanates of the hyperbranched polyurea with a tertiary amine compound that is functionalized with —OH, —NH2, —SH, or —COO—; and (c) quaternization of said tertiary amine groups by reacting with an alkylating agent to obtain a quaternized hyperbranched polymer having antimicrobial surfactant properties.

Abstract: Anhydrous oral care compositions and methods for preventing phase separation in the anhydrous oral care composition are disclosed. The oral care composition may include an orally acceptable vehicle, a thickening system, and a whitening agent. The orally acceptable vehicle may include propylene glycol, and the thickening system may include a polymeric thickener. The polymeric thickener may be or include a copolymer of 2-acrylamidomethylpropanesulphonic acid or a salt thereof.

Abstract: The present invention relates to a capsule comprising a pigment and a method for producing the same. More specifically, the present invention relates to a capsule which comprises therein a pigment inside which is likely to be discolored due to external environment, and thereby can easily crack or break and cause color development when applied to the skin, while isolating the pigment from the external environment, and a method for producing the same.

Abstract: The invention relates to the field of medicine and pharmaceuticals and particularly to a novel dosage form of an antitumor preparation, which ensures the hydrolytic and physical stability of said preparation, as well as to a method for producing a dosage form of this type. The stable dosage form is a lyophilizate comprising an etidronate-cytarabine conjugate or a pharmaceutically acceptable salt thereof, and a stabilizer, which is a divalent metal salt, in a molar ratio of stabilizer to conjugate of 1:1 to 20:1. A dosage form of this type ensures the hydrolytic and physical stability of the conjugate during long-term storage, and the stability of solutions of the conjugate for parenteral administration during clinical use.

Abstract: The present invention relates to an effective formulation for the treatment or the prevention of irritable bowel syndrome, a method for treating irritable bowel syndrome, and processes for preparing such formulations.

Abstract: The present invention relates to a pharmaceutical composition comprising compound having a log P of at least 5 and a vehicle, wherein the vehicle comprises (a) a fat component in an amount sufficient to achieve lymphatic absorption in a mammal, wherein the fat component is selected from a mono-glyceride of long chain fatty acids, a tri-glyceride of long chain fatty acids, and a mono- and tri-glyceride of long chain fatty acids.

Abstract: The invention relates to a composition, in particular a cosmetic composition, characterized in that it comprises:—at least one monoglyceride,—at least one tartaric ester of monoglycerides based on C12-C22,—at least one UV filter,—at least one HLB surfactant greater than 10, and—at least one hydrophilic gelling agent wherein the content of said one or more surfactant(s) having a HLB greater than 10 is comprised between 0.2% and 10% by weight, based on the total weight of the composition.

Abstract: The present invention relates to compositions for and methods of retarding hair loss or facilitating hair growth comprising a hair growth active, a C8-C24 alcohol ester of a carboxylic acid and a viscosity modifying agent comprising: a nonionic hydroxypropylmethyl cellulose and a high molecular weight carboxymethyl cellulose at a ratio of the nonionic hydroxypropylmethyl cellulose to the high molecular weight carboxymethyl cellulose of greater than about 1:1.

Abstract: This disclosure relates to compounds and compositions for forming bone and methods related thereto. In certain embodiments, the disclosure relates to methods of forming bone comprising implanting a bone graft composition comprising a growth factor such as BMP in a subject at a site of desired bone growth or enhancement in combination with a JAB1 blocker.

Abstract: A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weight of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.

Abstract: In a patch comprising a support layer and an adhesive agent layer, the adhesive agent layer comprises free asenapine, a maleic acid alkali salt, and a rubber-based adhesive agent.

Abstract: A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.

Abstract: Advantageously, para-chloroaniline (PCA) is minimal in antimicrobial articles prepared according to the method of the invention. A method of forming an antimicrobial article according to the invention comprises steps of: providing a polymerizable composition; incorporating an antimicrobially effective amount of at least one chlorhexidine-containing antimicrobial agent into the polymerizable composition; and, polymerizing the polymerizable composition to form chlorhexidine-containing polymer of the antimicrobial article, wherein processing temperature during the method is less than about 80° C.